Recently Hasegawa group also reported SGLT2 was elevated during early stages of DKD, which could upregulate intracellular glucose levels in proximal tubules and subsequently decrease SIRT1 expression whereas SGLT2 inhibitors preserved SIRT1 expression (102). This evidence concerns the gene SLC5A2 and diabetic kidney disease.